Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2026 | CAIX expression in urothelial cancer

Dickon Hayne • 13 Mar 2026
EAU 2026
Bladder Cancer Genitourinary Cancer

Dickon Hayne, MBBS, MD, FRCS, FRACS, UWA Medical School, Perth, Australia, discusses the expression of carbonic anhydrase 9 (CAIX) in urothelial cancer, noting that while it is generally good, the expression can be variable. Dr Hayne mentions that receptor studies have identified the presence of CAIX in various tumors, including breast and urogenital cancers, and comments on the use of this marker in staging urothelial cancer. This interview took place at the 41st Annual EAU Congress in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Dickon Hayne

ANZUP 1301: effects on urinary symptoms and other aspects of HRQL
2:38
ANZUP 1301: effects on urinary symptoms and other aspects of HRQL
Dickon Hayne • 15 Mar 2026
G-DISCO: synchronous gemcitabine and docetaxel as an intravesical therapy for high-risk NMIBC
1:51
G-DISCO: synchronous gemcitabine and docetaxel as an intravesical therapy for high-risk NMIBC
Dickon Hayne • 15 Mar 2026
ZiPUP: 89Zirconium-labelled girentuximab PET in patients with urothelial cancer
4:43
ZiPUP: 89Zirconium-labelled girentuximab PET in patients with urothelial cancer
Dickon Hayne • 13 Mar 2026
ANZUP 1301: BCG + mitomycin a promising alternative to BCG alone for high-risk bladder cancer
1:03
ANZUP 1301: BCG + mitomycin a promising alternative to BCG alone for high-risk bladder cancer
Dickon Hayne • 31 May 2025

Related Videos

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals